1-4 of 4
Hope Qamoos
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Results from the Randomized, Multicenter, Global Phase 3 BOREAS Study: Navtemadlin Versus Best Available Therapy in JAK Inhibitor Relapsed / Refractory Myelofibrosis

John O. Mascarenhas, Viola Maria Popov, Sanjay Mohan, Zübeyde Nur Özkurt, Jean-Jacques Kiladjian, Haifa Kathrin Al-Ali, Andrew Perkins, Zhuying Huang, Hope Qamoos, Jesse McGreivy, Wayne Rothbaum, Srdan Verstovsek, Maciej Kaźmierczak
Journal: Blood
Blood (2024) 144 (Supplement 1): 1000.
https://doi.org/10.1182/blood-2024-201642
Published: 2024
Journal Articles

Safety, Tolerability, and Efficacy of Axatilimab, a CSF-1R Humanized Antibody, for Chronic Graft-Versus-Host Disease after 2 or More Lines of Systemic Treatment

Stephanie J. Lee, Mukta Arora, Zachariah Defilipp, Mohammad Issam Abu Zaid, Antonio Di Stasi, Vedran Radojcic, Michael L. Meyers, Hope Qamoos, Peter Ordentlich, Christine Quaranto, Aaron Schmitt, Yu Gu, Amandeep Salhotra, Iskra Pusic, Carrie Lynn Kitko
Journal: Blood
Blood (2021) 138 (Supplement 1): 263.
https://doi.org/10.1182/blood-2021-146050
Published: 2021
Journal Articles

A Phase 1b-2 Study of KRT-232, a First-in-Class, Oral, Small Molecule Inhibitor of Murine Double Minute 2 (MDM2), in Combination with Acalabrutinib for the Treatment of Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) or R/R Diffuse Large B-Cell Lymphoma (DLBCL)

Peter Hillmen, MBChB, PhD FRCP, FRCPath, Hope Qamoos, CNP, Anne Uyei, MD, Wayne M. Rothbaum, Wojciech Jurczak, MD PhD, Catherine Thieblemont, MD PhD, John C. Byrd, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 23–24.
https://doi.org/10.1182/blood-2020-134901
Published: 2020
Journal Articles

An Open-Label, Global, Multicenter, Phase 1b/2 Study of KRT-232, a First-in-Class, Oral Small-Molecule Inhibitor of Murine Double Minute 2 (MDM2), Combined with Ruxolitinib in Patients Who Have Myelofibrosis and a Suboptimal Response to Ruxolitinib

John Mascarenhas, MD, Alessandro M. Vannucchi, MD, Adam J. Mead, MD PhD, Regina Garcia-Delgado, MD, Andrzej Pluta, MD, Hope Qamoos, CNP, Anne Uyei, MD, Damaj Gandhi Laurent, MD PhD, Haifa K Al-Ali
Journal: Blood
Blood (2020) 136 (Supplement 1): 44–45.
https://doi.org/10.1182/blood-2020-134262
Published: 2020